---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002888"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:12:14.556435+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allogene to start pivotal ALPHA3 trial in 1L LBCL; cuts 22% staff, partners with Foresight

## Summary
- Workforce reduction of ~22% with estimated $5.0M-$5.5M in severance charges, mostly in Q1 2024.
- Strategic collaboration with Foresight Diagnostics to develop MRD assay; Allogene to fund ~$26M.
- Plans to initiate pivotal Phase 2 ALPHA3 trial mid-2024 for cema-cel in 1L LBCL, targeting MRD+ patients (n~230).
- Deprioritizing 3L trials ALPHA2 and EXPAND; expects CD19 CAR T 2L/3L market to diminish.

## SEC filing metadata
- accession: 0001193125-24-002888
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/d103673d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002888
- JSON: https://secwatch.observer/filing/0001193125-24-002888.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002888.txt

## Key facts
- Material Agreements
  Allogene Therapeutics, Inc. entered into Strategic Collaboration Agreement with Foresight Diagnostics, Inc. (effective 2024-01-03).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Foresight Diagnostics, Inc.
  - Effective: 2024-01-03
  source text: On January 3, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into a Strategic Collaboration Agreement (the “Agreement”) with Foresight Diagnostics, Inc. (“Foresight”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm
- Restructurings & Charges
  Allogene Therapeutics, Inc. announced a restructuring with charges of reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical devel affecting workforce (approximately 22% of the Company’s employees).
  - Type: restructuring
  - Charge: reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical devel
  - Affected area: workforce
  - Headcount: approximately 22% of the Company’s employees
  source text: On January 4, 2024, the Company’s Board of Directors approved a reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical development strategy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm
- Restructurings & Charges
  Allogene Therapeutics, Inc. announced a restructuring with charges of charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits affecting financial.
  - Type: restructuring
  - Charge: charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits
  - Affected area: financial
  source text: The Company estimates that it will incur charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits, primarily in the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.